Five patients with adult-onset metachromatic leukodystrophy (MLD) underwent allo-SCT. Conditioning was reduced in intensity and grafts were obtained from voluntary unrelated donors. All but one graft were depleted of T-lymphocytes. Patient age at transplantation varied from 18 to 29 (median, 27) years. Two patients rejected their graft and MLD progressed. The recipient of the unmanipulated graft converted to complete donor chimerism with normalization of arylsulphatase A (ARSA) levels. Despite ARSA normalization, he deteriorated. Another patient was a mixed chimera. Following escalated doses of donor lymphocyte infusions he converted to complete donor chimerism. His levels of ARSA correlated positively with the percentage of donor cells and MLD was not progressive. The fifth patient died after 35 days from complications associated with GVHD. We conclude that results of allo-SCT in symptomatic MLD patients are poor. However, allo-SCT may stop progression of MLD in selected patients.
Introduction
Metachromatic leukodystophy (MLD) is a progressive, autosomal recessively inherited disorder in which the enzyme arylsulphatase A (ARSA) is deficient. Deficiency of ARSA results in the accumulation of sulfatides in the central and peripheral nervous systems, kidney and other visceral organs. This accumulation is associated with progressive demyelination. According to the age of onset of the first symptoms, MLD is divided into early infantile (o1 year), late infantile (1-2 years), early juvenile (2-6 years), late juvenile (6-16 years) and the adult form (X16 years). The main symptoms of the adult form are mental deterioration, psychiatric symptoms and urinary incontinence. 1, 2 The course is slowly progressive, variable and has a mean survival of 12 years after disease onset. 3 SCT has been used to treat several lysosomal storage diseases. 4 After SCT, donor-derived cells can migrate into the central nervous system and can mediate the crosscorrection of ARSA in neighboring neuronal and glial cells. 5 It is important to perform the transplant as early as possible to prevent irreversible neurological damage. In late-juvenile and adult-onset MLD, some enzyme activity is left and neurological progression is relatively slow making treatment with SCT possible before irreversible neurological damage has occurred. 2 We report our experience with allo-SCT in five patients with adult-onset MLD and show that transplantation was successful in one patient.
Patients and methods

Patients
The patients 0 symptoms were progressive and included changed behavior, memory loss, psychotic episodes, ataxia and urinary incontinence. Magnetic resonance imaging (MRI) brain scans showed white matter lesions and cerebral atrophy. All patients had results of electromyography compatible with a demyelinating polyneuropathy. Visual evoked potentials (VEPs) showed increased latencies in all patients. The diagnosis was confirmed by low ARSA levels, increased sulfatide excretion in the urine and ARSA gene mutations. Transplants were performed 0.5-2 (median, 1) years after onset of MLD. All patients or their guardians gave informed consent for the procedure. Characteristics of the patients are given in Table 1 .
Donors
All donors had normal ARSA activity and details of the donors are given in Table 1 .
Conditioning and graft characteristics
Conditioning regimens were reduced in intensity and are given in Table 1 . All but one graft (for patient C) were partially depleted of T lymphocytes using counterflow centrifugation or CD34 or CD3/CD19 immunomagnetic selection (Miltenyi Biotec, Bergisch Gladbach, Germany). 7 Details are given in Table 1 .
Post transplant immunosuppression, supportive care, GVHD and chimerism Patient C received CsA and mycophenolate mofetil as immunoprophylaxis post transplantation. The other patients were given only CsA for 3 months.
All patients were managed in single rooms with filtered air under positive pressure during their hospital stay. They received oral selective gut decontamination, cotrimoxazole for Pneumocystis jiroveci prophylaxis and oral valacyclovir for prophylaxis of herpes infections.
Acute GVHD was classified from grade 0 to 4 according to the criteria described by Glucksberg et al. 6 and chronic GVHD was graded as none, limited or extensive. 7 Chimerism was analyzed with a real-time PCR method using single-nucleotide polymorphisms (SNPs). 8 Biochemical assays and DNA analysis ARSA levels in leukocytes and sulfatide levels in the urine were assayed as described before. 9, 10 ARSA mutation analysis was performed as described by Innis et al.
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Neuropsychologic, radiologic and neurophysiologic examinations and follow-up Activity of daily living was followed up by means of the Barthel index.
12-14 The highest score is 100 and indicates that a person is able to do most activities independently. Measurements were made 10-19 months before transplantation and 9-13 months after SCT.
All Before and after transplantation, MRI brain scans were made. 21 Nerve conduction studies were performed, including the left median nerve and both suralis nerves. 22 In all but patient C, VEPs were measured, using the checkerboard method. If the patient was not able to focus, the flash VEP method was used. 23 For nerve conduction studies, specific attention was given to reduce conduction velocity and for VEP to increased potential 100 latencies, both indicative of demyelinating disease. Whenever possible, these tests were repeated after SCT. 
Definitions
The first day of engraftment was the first of three consecutive days on which leukocytes were X1.0 Â 10 9 /L. If leukocytes never reached X1.0 Â 10 9 /L and BM biopsy was without haematopoietic cells, the patient had a primary rejection or take failure. When leukocytes disappeared after engraftment and during further follow-up, patient had a secondary rejection.
Results
Patient A Patient A became disoriented in time and place. Consequently, he was no longer able to perform his job as a lorry driver. His neurological condition worsened and 3 years later, he was diagnosed with MLD. He was transplanted with a graft from a voluntary unrelated donor and engrafted after 19 days. He had no acute or chronic GVHD and no infections. At 4 weeks after transplantation, ARSA levels reached a maximum of 38 nmol/h per mg protein. However, after 6 months, he rejected the graft and enzyme activity decreased to 9 nmol/h per mg protein. Biological and neurological parameters are given in Table 2 . Now, he is fed through a percutaneous endoscopic gastrostomy tube and lives with his parents with full-time support of a nurse.
Patient B
This patient had a normal development and graduated at an academic level. At the age of 29 years, she was diagnosed with MLD. She was transplanted with a graft from a voluntary unrelated donor. During the transplantation period, increased memory loss, confusion, fecal and urinary incontinence, and gait disorders were noted. She did not suffer from infections. Primary graft failure occurred and the patient had autologous regrowth. 8 Because of the poor clinical condition of the patient, she was not retransplanted. Her ARSA level remained low, with 4 nmol/h per mg protein. No follow-up data are available for IQ, MRI, nerve conduction studies and VEP. Neurological condition decreased with ataxia and memory disturbances and at this moment, 6 years after transplantation, she is nursed in a nursing home. Table 2 ). At this moment, 9 years after SCT, he is living in a nursing home.
Patient C
Just after finishing high school, this patient suffered from depression. He had psychotic episodes and auditory hallucinations. Between the psychotic episodes, he developed concentration disturbances and memory disorders. At 7 years after the first symptoms, the patient was diagnosed with MLD. He was transplanted with an unmanipulated graft at the Department of Hematology and Oncology of the University of Leipzig, Germany. After transplantation, he developed acute GVHD grade 2 of the intestine and skin for which he was treated with corticosteroids and UVB phototherapy. From 13 weeks after SCT onwards, he had only donor blood cells and ARSA levels between 62 and 72 nmol/h per mg protein. Despite normal ARSA levels, his neurological symptoms deteriorated further (see
Patient D
After a traffic incident, patient D had memory disturbances and behavioral changes. He was known to have learning difficulties but motor development was normal. The diagnosis of MLD was made. SCT was performed and the patient was engrafted at day 9. He had acute GVHD grade 2 of the skin and gut. ARSA activity raised and the patient had mixed chimerism at 3 months. To convert mixed chimerism into complete donor chimerism and to enhance the level of ARSA, the patient was given escalated Table 2 Biological and neurological parameters before and after SCT Table 2 . Now, he is independent for most of the daily activities and lives with his parents. More than 7 years after DLI resulting in complete donor chimerism, no further progression of disease has been observed.
Patient E
This patient is the younger sister of patient D. Her parents had noticed learning difficulties and behavioral changes from 1 year of age. She needed a wheelchair owing to ataxia. As her only sibling suffered from MLD, she was transplanted with a one DRB1-locus mismatched unrelated donor. She engrafted 10 days after SCT and developed acute GVHD grade 3 of the skin, gut and liver. Treatment was with high doses of methylprednisolone, but she deteriorated neurologically and started having epileptic seizures. Progression of cerebral atrophy was seen on MRI brain scan. She developed thrombotic thrombocytopenic purpura. CsA was discontinued, but she died 35 days after transplantation. At autopsy, severe GVHD of gut, liver and skin was confirmed. Microangiopathy was demonstrated in the kidneys and pulmonary vessels. The brain showed abnormalities compatible with MLD and also signs of microangiopathy. Because of her early death, measurement of ARSA activity was not possible after SCT.
Discussion
Although more than 100 MLD patients worldwide have been transplanted, publications are limited. 24 Four adult MLD patients who engrafted after SCT have been described by Krivit et al. 25 Only one patient improved. Solders et al. 26 reported a hematopoietic SCT from an HLA-identical sibling in a 28-year-old woman. After a history of 4 years of frontal dementia, the diagnosis of MLD was made. After transplantation, normal enzyme levels, increased IQ, stable MRI and improved nerve conduction were demonstrated. Shapiro et al. analyzed the neuropsychological outcome in six patients with late-juvenile and adult-onset MLD treated with SCT. 27 No data were given about the donors, engraftment, ARSA activity, nor about sulfatide levels. However, IQ scores stabilized in three out of six patients. Two patients died from transplant-related complications. The last patient had considerable loss of mental function, but follow-up and IQ were not given. Kocȩ t al. treated six patients with the infusion of MSC from the original donor after successful SCT from an HLA-identical sibling. 28 Four of them had adult-onset MLD and two had juvenile-onset MLD. Nerve conduction studies of peroneal nerve showed improvement in four patients. Mesenchymal cells were also given to a 23-year-old woman with adultonset MLD, reported by Meuleman et al. 29 The donor was an HLA-identical sibling. At day 30 after SCT, 83% of the CD3 and 73% of the CD33 cells were from donor origin.
ARSA levels increased to normal, and neurological manifestations and MRI stabilized.
In the present study, five patients with adult-onset MLD were treated with SCT, with stem cells from voluntary unrelated donors. The interval between the first symptoms and the diagnosis of MLD was long with a median of 3 years and during that period, progression of neurologic damage continued. All patients were transplanted with grafts from unrelated donors as HLA-identical siblings were not available. MLD is an autosomal recessive disease, which means 50% of the siblings are heterozygous for the MLD mutation. ARSA activity in these heterozygotes is lower in comparison with controls, although without overt clinical consequences. 1, 30, 31 In patients transplanted for Hurler syndrome, a higher enzyme level is associated with a significantly reduced substrate 32 and this was also true for MLD mice. 5 GVHD may negatively influence the long-term outcome, probably owing to enhancing inflammation and inflammation is a hallmark of many lysosomal storage diseases. 5 GVHD is associated with the graft-versus-tumor effect and GVT is an important effect after transplantation for hematological malignancies but not after SCT for MLD. To prevent GVHD, we used partial T-cell depletion in four of our patients. Despite partial T-cell depletion, patient E developed severe acute GVHD. During acute GVHD and its treatment, she deteriorated neurologically.
One of the five patients had a take failure and a second patient suffered from secondary rejection. High rejection rates of 15-75% are found in SCT for storage diseases. Risk factors are mismatched grafts, grafts from unrelated donors, T-cell depletion of the graft, sensitized patients and conditioning with a regimen that is reduced in intensity. 33, 34 Furthermore, rejection can be facilitated by the relatively immunocompetent state of the patient as these patients do not suffer from a hematological disease and have not been pretreated.
Two of our patients converted to complete donor chimerism, which led to normalization of ARSA activity. Despite normal ARSA levels, patient C continues to suffer from progressive disease, which has already led to severe disablement. In this patient, SCT was performed 9 years after onset. Probably, neurological damage was too extensive to enable stabilization of disease with SCT. Previous reports of MLD and other leukodystrophies have made recommendations to transplant patients in an early age and disease to prevent serious neurological damage. 25, [35] [36] [37] In patient D, MRI showed progression of white matter lesions in the period of lower enzyme levels but remained stable during further follow-up. DLI was necessary to convert mixed chimerism into complete donor chimerism, resulting in higher levels of ARSA and stabilization of cerebral progression.
In most published cases of MLD, SCT seems not to be effective. New therapies are in development. Enzyme replacement therapy by i.v. injection of the therapeutic enzyme is a successful treatment in lysosomal storage diseases without central nervous system involvement. In MLD, the therapeutic impact of this strategy is greatly reduced as the blood-brain barrier severely limits access to the nervous tissue. 24 Lentiviral vectors enable efficient gene marking of mouse and human hematopoietic stem cells, and ARSA overexpression in the differentiated progeny. 5, 24 Studies with intracerebral delivery of ARSA by an adenoassociated virus in non-human primates have been performed, which demonstrated increased intrahemispheral enzyme activity. 5, 38 Sustained expression of ARSA is also possible after stereotactic injection of recombinant viral vectors into the brain. An alternative approach to gene therapy is the direct engraftment of oligodendroglial progenitors, neural progenitors or embryonic stem cells into the central nervous system of the patient using the regenerative capacity and cross-corrective activity of these cells.
We conclude that stabilization of adult MLD after SCT occurred in only one of the five patients. MLD is a severe disease and no other effective therapies are available for clinical use at this moment. An overview of the long-term outcome of the more than 100 worldwide transplanted MLD patients is strongly needed. SCT should be performed in clinical trials for a limited subset of selected patients.
